Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
845 stopped studies mapped to Malignant Bone Marrow Neoplasm and descendants · 88% state a reason
Over the 845 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04553692 | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with… | Phase 1 | terminated | Sep 17, 2020 | IGM Biosciences, Inc. | Study terminated due strategic corporate pivot to focus on auto-immune indications | Sponsor / business decision |
| NCT06351306 | DEC-C and Thioguanine for R/R AML | Phase 2 | withdrawn | Apr 8, 2024 | Columbia University | Difficultly enrolling | Enrollment / accrual |
| NCT03746054 | Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the…(PALERMO) | Phase 3 | terminated | Nov 19, 2018 | University Hospital, Angers | Inclusions stopped on 25MAR2022 due to lack of inclusion Last follow-up on 16APR2024 | Other (stated, no rule matched) |
| NCT06113289 | A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia | Phase 1 / Phase 2 | withdrawn | Nov 2, 2023 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT04477291 | A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS | Phase 1 | terminated | Jul 20, 2020 | Aptose Biosciences Inc. | Change in corporate strategy | Sponsor / business decision |
| NCT06068868 | Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in… | Phase 1 | terminated | Oct 5, 2023 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT02291965 | Blood Samples to Identify Biomarkers of Busulfan | — | terminated | Nov 17, 2014 | Fred Hutchinson Cancer Center | Study terminated due to end of funding | Funding |
| NCT06110208 | Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r… | Early Phase 1 | terminated | Oct 31, 2023 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Collaborator's decision | Other (stated, no rule matched) |
| NCT03686345 | Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor…(AML FLT3) | Phase 2 | terminated | Sep 26, 2018 | Niguarda Hospital | didn't reach the primary endpoint | Other (stated, no rule matched) |
| NCT04905407 | Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute… | Phase 2 | terminated | May 27, 2021 | Syros Pharmaceuticals | As per sponsor decision, the study was terminated. | Sponsor / business decision |
| NCT04778397 | Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of…(ENHANCE-2) | Phase 3 | terminated | Mar 3, 2021 | Gilead Sciences | Study discontinued due to futility. | Efficacy / futility |
| NCT04342962 | Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia | Phase 2 | terminated | Apr 13, 2020 | Gruppo Italiano Malattie EMatologiche dell'Adulto | poor enrollment | Enrollment / accrual |
| NCT06200441 | Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and… | — | withdrawn | Jan 11, 2024 | Ugur Arzu Kulu | Kits were not available due to lack of sponsorship | Other (stated, no rule matched) |
| NCT01743807 | Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia | Phase 1 | terminated | Dec 6, 2012 | Therapeutic Advances in Childhood Leukemia Consortium | SBI Biotech (supplier) decided to no longer support the study or GNKG168. | Other (stated, no rule matched) |
| NCT04887259 | Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML | Phase 1 | terminated | May 14, 2021 | Lava Therapeutics | The decision to discontinue LAVA-051clinical trial follows a recent review of the competitive… | Safety / toxicity |
| NCT02398825 | Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid… | Phase 2 | terminated | Mar 26, 2015 | Gruppo Italiano Malattie EMatologiche dell'Adulto | low enrollment rate | Enrollment / accrual |
| NCT04914676 | Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With… | Phase 2 | terminated | Jun 4, 2021 | University of Florida | PI decision to close study early due to limited data due to accrual goal not being met | Enrollment / accrual |
| NCT04083170 | Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic… | Phase 2 | terminated | Sep 10, 2019 | Fred Hutchinson Cancer Center | The federal funding period ended. The study was originally intended to be multi-site but was only… | Enrollment / accrual |
| NCT04029688 | A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of… | Phase 1 / Phase 2 | terminated | Jul 23, 2019 | Hoffmann-La Roche | Study was terminated by the sponsor based on insufficient tolerability and efficacy to proceed… | Efficacy / futility |
| NCT03755518 | A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary…(FREEDOM) | Phase 3 | terminated | Nov 28, 2018 | Celgene | Slow accrual. | Enrollment / accrual |
| NCT04310592 | Natural Killer Cell (CYNK-001) Infusions in Adults with AML(CYNK001AML01) | Phase 1 | terminated | Mar 17, 2020 | Celularity Incorporated | Business reasons | Sponsor / business decision |
| NCT04526795 | Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory… | Phase 1 | terminated | Aug 26, 2020 | M.D. Anderson Cancer Center | Administratively Complete | Other (stated, no rule matched) |
| NCT04282668 | A Study of TAS1440 With ATRA in Subjects With r/r AML | Phase 1 | terminated | Feb 25, 2020 | Taiho Oncology, Inc. | The study was terminated due to the changing treatment landscape, difficulty in enrolling eligible… | Enrollment / accrual |
| NCT04582864 | Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)… | Phase 2 | terminated | Oct 12, 2020 | Washington University School of Medicine | The sponsor is no longer supporting the drug | Other (stated, no rule matched) |
| NCT03939585 | Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells… | Phase 1 | withdrawn | May 7, 2019 | Leland Metheny | Lack of funding | Funding |
| NCT04755244 | A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia… | Phase 1 | terminated | Feb 16, 2021 | ALX Oncology Inc. | While intended to be a Phase 1/2 clinical study, the study never moved forward to Phase 2. | Other (stated, no rule matched) |
| NCT04808115 | IIT PH1 KDS-1001 in Patients With CML | Phase 1 | withdrawn | Mar 22, 2021 | Duke University | Study halted prematurely, prior to enrollment of first participant. | Enrollment / accrual |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT05266950 | Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory… | Phase 1 | withdrawn | Mar 4, 2022 | Beijing Boren Hospital | Difficulty in joining the group | Other (stated, no rule matched) |
| NCT04762875 | MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in… | Phase 2 | terminated | Feb 21, 2021 | Ensoma | This study was voluntarily terminated due to a business decision not to proceed and not due to any… | Safety / toxicity |
| NCT05601466 | Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia | Phase 1 | terminated | Nov 1, 2022 | Institute of Hematology & Blood Diseases Hospital, China | It did not reach the expected results of clinical trial | Other (stated, no rule matched) |
| NCT02610062 | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of… | Phase 1 | terminated | Nov 20, 2015 | Astellas Pharma Global Development, Inc. | Business decision by sponsor | Sponsor / business decision |
| NCT04521946 | Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade… | Phase 1 | withdrawn | Aug 21, 2020 | M.D. Anderson Cancer Center | No participants enrolled. | Enrollment / accrual |
| NCT02864290 | A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in… | Phase 1 | terminated | Aug 12, 2016 | Astellas Pharma Global Development, Inc. | Study was terminated due to lack of efficacy. | Efficacy / futility |
| NCT02270463 | SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in… | Phase 1 / Phase 2 | terminated | Oct 21, 2014 | Stemline Therapeutics, Inc. | not stated | Not stated |
| NCT03541369 | Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With…(20170528) | Phase 1 | terminated | May 30, 2018 | Amgen | Premature discontinuation of study, a strategic decision. | Sponsor / business decision |
| NCT04982354 | Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia | Phase 1 / Phase 2 | withdrawn | Jul 29, 2021 | Guenther Koehne | Could not accrue | Enrollment / accrual |
| NCT03735875 | Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory… | Phase 1 / Phase 2 | terminated | Nov 8, 2018 | M.D. Anderson Cancer Center | This study was terminated early due to other competing trials, therefore did not go on to the Phase… | Other (stated, no rule matched) |
| NCT03884829 | A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS | Phase 1 | terminated | Mar 21, 2019 | Cyclacel Pharmaceuticals, Inc. | Switch to oral formulation of CYC140 (plogosertib) | Other (stated, no rule matched) |
| NCT05005182 | Luspatercept With or Without Hydroxyurea for the Treatment of… | Phase 2 | terminated | Aug 13, 2021 | Mayo Clinic | Slow accrual | Enrollment / accrual |
| NCT05682170 | Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | terminated | Jan 12, 2023 | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | Sponsor decision | Sponsor / business decision |
| NCT05823480 | Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with… | Phase 1 | withdrawn | Apr 21, 2023 | City of Hope Medical Center | Withdrawn -ctms | Other (stated, no rule matched) |
| NCT05854966 | CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid… | Phase 2 | withdrawn | May 11, 2023 | Wake Forest University Health Sciences | PI decided not to move forward with the study | Other (stated, no rule matched) |
| NCT06586099 | Tislelizumab with Azacitidine in the Treatment of R/R AML | Phase 1 / Phase 2 | withdrawn | Sep 19, 2024 | Institute of Hematology & Blood Diseases Hospital, China | withdrawn | Other (stated, no rule matched) |
| NCT03154827 | Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance… | Phase 1 / Phase 2 | terminated | May 16, 2017 | BioLineRx, Ltd. | Due to lack of enrollment | Enrollment / accrual |
| NCT03530683 | A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801),… | Phase 1 | terminated | May 21, 2018 | Pfizer | A business decision was made by Pfizer to terminate the study. Termination was not due to any… | Safety / toxicity |
| NCT03603964 | Guadecitabine Extension Study | Phase 2 | terminated | Jul 27, 2018 | Astex Pharmaceuticals, Inc. | Early termination not due to patient safety | Safety / toxicity |
| NCT05569512 | Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation… | Phase 1 | terminated | Oct 6, 2022 | Malika Kapadia | On 7/26/24 the Sponsor-Investigator was notified GlycoMimetics was terminating contracting for… | Investigator |
| NCT06007911 | Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With… | Phase 1 | withdrawn | Aug 23, 2023 | Medical College of Wisconsin | Sponsor withdrew support. | Other (stated, no rule matched) |
| NCT02353143 | Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia(ARMY) | Phase 1 | terminated | Feb 2, 2015 | Menarini Group | The Sponsor accepted the iDSMB recommendation to terminate the study due to evidence of… | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 28, 2025source: clinicaltrials